✦ The floor
Discussion
Signed responses from readers of the wire.
✦ Clinical Takeaway ✦
This is an author reply to a letter to the editor and does not introduce new data; no change to current practice is warranted until the full exchange is evaluated in context of the original Phase IIIB trial findings.
✦ Why It Matters ✦
Cisplatin-induced tinnitus is a significant and often irreversible side effect of cancer chemotherapy, and any validated preventive intervention would have direct clinical value for oncology audiology programs.
✦ Key Points ✦
- 01Author reply addresses a letter to the editor critiquing a Phase IIIB RCT on intratympanic dexamethasone.
- 02The original trial evaluated prevention of cisplatin-induced tinnitus, a common ototoxic side effect.
- 03Published in Ear & Hearing, a peer-reviewed audiology journal.
- 04No new primary data are presented in this correspondence.
- 05The exchange may clarify methodological or interpretive questions raised about the original RCT.
✦ Claims & Evidence ✦
ClaimEvidenceSupport
Intratympanic dexamethasone can prevent cisplatin-induced tinnitus based on a Phase IIIB RCT.
studypartially supported✦ Research metadata ✦
- PMID
- 42566269
- DOI
- 10.1097/AUD.0000000000001878.
- Journal
- Ear and Hearing
- Publication type
- editorial
- Evidence level
- 1b
- Population
- Cancer patients receiving cisplatin chemotherapy at risk for tinnitus
- Intervention
- Intratympanic dexamethasone injection
- Comparator
- Control/placebo (as per original RCT design)
Primary outcomes
Prevention of cisplatin-induced tinnitus